These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Diagnosing leptomeningeal carcinomatosis with negative CSF cytology in advanced prostate cancer. Bernstein WB; Kemp JD; Kim GS; Johnson VV J Clin Oncol; 2008 Jul; 26(19):3281-4. PubMed ID: 18591564 [No Abstract] [Full Text] [Related]
4. Combination chemotherapy for hormone-refractory prostate carcinoma: progress and pitfalls. Syed S Cancer; 2003 Nov; 98(10):2088-90. PubMed ID: 14601076 [No Abstract] [Full Text] [Related]
5. Chemotherapy of advanced prostatic carcinoma. Millikan RE Semin Oncol; 1999 Apr; 26(2):185-91. PubMed ID: 10597729 [TBL] [Abstract][Full Text] [Related]
6. [Combined hormone and chemotherapy for the patients with advanced prostate cancer]. Uekado Y; Hirano A; Inagaki T; Hiroi A; Watanabe T Gan To Kagaku Ryoho; 1995 Jul; 22(8):1041-5. PubMed ID: 7611755 [TBL] [Abstract][Full Text] [Related]
7. [A case report of paclitaxel combined with carboplatin for poorly differentiated prostate cancer with renal failure]. Chen JW; Meng QG; Tang Y; Xie D; Wang ZR Ai Zheng; 2007 Apr; 26(4):445-6. PubMed ID: 17430671 [No Abstract] [Full Text] [Related]
8. [Advanced cancer of the prostate: chemotherapy]. Garcia-Giralt E; Palangie T; Dorval T; Jouve M; Pouillart P Bull Cancer; 1986; 73(1):68-73. PubMed ID: 3779125 [TBL] [Abstract][Full Text] [Related]
9. [Role of mitoxantrone in the treatment of hormone-independent metastatic cancer of the prostate]. Culine S Prog Urol; 2002 Feb; 12(1 Suppl 2):31-5. PubMed ID: 11980025 [No Abstract] [Full Text] [Related]
10. [Orimeten in the treatment of advanced prostatic carcinoma]. Vachalovský V; Vomácka V Rozhl Chir; 1988 Oct; 67(10):666-70. PubMed ID: 3206313 [No Abstract] [Full Text] [Related]
11. Chemotherapy of hormonally unresponsive prostatic carcinoma. deKernion JB; Lindner A Urol Clin North Am; 1984 May; 11(2):319-26. PubMed ID: 6233779 [TBL] [Abstract][Full Text] [Related]
12. The role of chemotherapy in the treatment of prostatic carcinoma. Tonato M; Bracarda S Rays; 1993; 18(1):87-93. PubMed ID: 8356244 [No Abstract] [Full Text] [Related]
13. A Phase I/II study of weekly paclitaxel and 3 days of high dose oral estramustine in patients with hormone-refractory prostate carcinoma. Ferrari AC; Chachoua A; Singh H; Rosenthal M; Taneja S; Bednar M; Mandeli J; Muggia F Cancer; 2001 Jun; 91(11):2039-45. PubMed ID: 11391583 [TBL] [Abstract][Full Text] [Related]
14. Successful treatment of poor prognostic patients with advanced prostatic carcinoma with the association of diethylstilbestrol and cyclophosphamide. Germá Lluch JR; Marcuello Gaspar E; de Andrés Basauri L; López Pousa A; López López JJ Rev Esp Oncol; 1982; 29(2):317-24. PubMed ID: 7188232 [TBL] [Abstract][Full Text] [Related]
15. Multicenter Phase II study of estramustine phosphate plus weekly paclitaxel in patients with androgen-independent prostate carcinoma. Vaughn DJ; Brown AW; Harker WG; Huh S; Miller L; Rinaldi D; Kabbinavar F Cancer; 2004 Feb; 100(4):746-50. PubMed ID: 14770430 [TBL] [Abstract][Full Text] [Related]
16. Management of newly diagnosed metastatic carcinoma of the prostate. Elder JS; Catalona WJ Urol Clin North Am; 1984 May; 11(2):283-95. PubMed ID: 6428022 [TBL] [Abstract][Full Text] [Related]
18. [Study of anti-cancer chemotherapy of prostatic carcinoma. I. Comparative study of ifosfamide and VIP against a hormone-independent human prostatic carcinoma cell line]. Moriyama N; Usui T; Nagafuji T; Ohsumi Y; Ishibe T Gan To Kagaku Ryoho; 1987 Aug; 14(8):2589-93. PubMed ID: 3619466 [No Abstract] [Full Text] [Related]
19. Small cell carcinoma of the prostate with excellent treatment results. Koukourakis G; Kouloulias V; Psyri A; Zacharias G; Maravelis G; Kostakopoulos A J BUON; 2008; 13(3):442-3. PubMed ID: 18979565 [No Abstract] [Full Text] [Related]